ArticleTissue engineering. Part A2021
Evaluation of Extracellular Matrix Composition to Improve Breast Cancer Modeling.
Article in Tissue engineering. Part A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- 3D Bioprinted Breast Cancer-Stroma Model with Tailored Migration-Permissive Bioink Reveals Impact of Adipose-Derived Stromal Cells on Cancer Cell Migration and Invasion Dynamics.Advanced healthcare materials · 2026Article
- Toward More Translational Tumor Models: Breast dECM-Based 3D Systems Capture Native Microenvironmental Cues.Bioengineering (Basel, Switzerland) · 2026Article
- Using biomaterial-based 3D in vitro cancer models to solve current clinical problems.British journal of cancer · 2026Review
- Integrative Raman Spectroscopy and Multi-Omics Analysis of Lipid and Matrix Protein Heterogeneity in Triple-Negative Breast Cancer.Chemical & biomedical imaging · 2026Article
- Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.Molecular therapy. Oncology · 2026Review
- The 3D Collagen Network as a Determinant of Tumor Progression and Drug Delivery Efficiency in Breast Cancer.Pharmaceutics · 2026Review
- Unlocking the Therapeutic Potential of Integrin-Linked Kinase Inhibitors in Bioengineered 3D Breast Tumor Stroma Models.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Dissecting Context-Specific Effects of ERK5 Signaling in Triple-Negative Breast Cancer.Cancers · 2026Article
- Type I collagen promotes triple-negative breast cancer progression through a UBE2V1-ACSL5 regulatory axis.Frontiers in oncology · 2026Article
- Evaluation of Metaplastic Triple-Negative Breast Cancer Extracellular Matrix Structure and Protein Composition.Bioengineering (Basel, Switzerland) · 2025Article
- Review
- Magnetic Resonance Elastography of Invasive Breast Cancer: Evaluating Prognostic Factors and Treatment Response.Tomography (Ann Arbor, Mich.) · 2025Article
- Extracellular matrix dysregulation in aging, calcification, and cancer diseases: insights into cellular senescence, inflammation, and novel therapeutic strategies.International journal of biological sciences · 2025Review
- Adipose Tissue in Breast Cancer Microphysiological Models to Capture Human Diversity in Preclinical Models.International journal of molecular sciences · 2024Review
- Exploring the interaction between extracellular matrix components in a 3D organoid disease model to replicate the pathophysiology of breast cancer.Journal of experimental & clinical cancer research : CR · 2023Review
- Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.Molecular cancer · 2023Review
- Differential Protein Citrullination in Human ER- and ER+ Tumor and Adjacent Healthy Breast Tissue.Biochemistry · 2023Article
- Advances in Tumor Organoids for the Evaluation of Drugs: A Bibliographic Review.Pharmaceutics · 2022Review
- Substrate Type and Concentration Differently Affect Colon Cancer Cells Ultrastructural Morphology, EMT Markers, and Matrix Degrading Enzymes.Biomolecules · 2022Article
- Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling.Stem cells and development · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of resistance to therapy is a significant obstacle to effective therapeutic regimens. Evaluating the effects of oncology drugs in the laboratory setting is limited by the lack of translational models that accurately recapitulate cell-microenvironment interactions present in tumors. Acquisition of resistance to therapy is facilitated, in part, by the composition of the tumor extracellular matrix (ECM), with the primary current
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.